Sanofi, OpenAI, Formation Bio announce AI drug development partnership

Andrew Dunn

Senior Biopharma Correspondent

French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi, OpenAI, Formation Bio announce AI drug development partnership

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Sanofi, Ope­nAI, For­ma­tion Bio an­nounce AI drug de­vel­op­ment part­ner­ship

Senior Biopharma Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Sanofi, OpenAI, Formation Bio announce AI drug development partnership